Skip to content

Life Sciences

Concurrent validation is the exceptional route

  • Life Sciences
  • 1 min read

Concurrent validation turns up in project meetings as a way to rescue a launch date.

The plan has three validation batches, the first is made, so the proposal is to release it now and finish the program while it sells.

EU GMP Annex 15 (2015) does let batches reach the market before validation is complete, and it says when. In exceptional circumstances, where there is a strong benefit-risk ratio for the patient, it may be acceptable not to complete a validation program before routine production starts, and concurrent validation could be used. The decision must be justified, documented in the validation master plan and approved by authorised personnel.

The test in that sentence is the patient's benefit and risk. A medicine in short supply that patients depend on can meet it. A project three months behind cannot, because the benefit is the company's. Its answer is in the schedule, with the validation batches and their laboratory time in the first baseline.

When the route is taken, there should be sufficient data to support the conclusion that each batch is uniform and meets its acceptance criteria, documented and available to the Qualified Person before certification.

Industries

Related

More on this subject

Engineering's part of the product quality review

The 2013 text of EU GMP Chapter 1 lists the qualification status of relevant equipment and utilities among the items a product quality review should include. Engineering can make that line believable with four more inputs: changes in the period, excursions and trends, calibration and maintenance failures with product impact, and the status of engineering CAPAs.

InsightRead